Nanoparticles as a platform for controlled delivery of therapeutics

November 10, 2011

Dr. Byron Gates from the Simon Fraser University in Burnaby, Canada was one of our runners up in the SPECTROstar Nano competition. He proposed using the SPECTROstar Nano for developing nanoparticle systems for specific applications in nanomedicine.

Image of Dr EJ Dell
Dr EJ Dell
PhD, Sales Manager Northwest

“We will use the unique properties of designer NPs [nanoparticles] decorated with chemical/biochemical elements to target specific cells or tissue where low-energy light will release known therapeutics. We will decorate a variety of [nanoparticles] of tailored size, shape and composition with organic molecules, known therapeutics and antibodies. The ability to deliver non-damaging, low energy light deep into tissue is a key feature of this research. The role of the NPs is to harness NIR light and convert it into higher-energy light or heat either in proximity to or within live cells. The goal of this release is to deliver therapeutics and change cell fate. The SPECTROstarNano will be essential to this project for preparing NIR-responsive NPs that are biocompatible and decorated with thermoresponsive and/or photoresponsive therapeutics that are optimized for release in biological systems. These designer NPs systems have the potential to make a huge commercial and scientific impact in a wide range of biomedical applications. The SPECTROstar Nano would significantly enhance our ability to develop [nanoparticle] systems for specific applications in nanomedicine. This developing sector has the possibility of being extremely important economically to world-wide markets, and for revolutionizing medical practice in disease treatment in the coming years.”

go to top